• 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodynam 2002; 21: 16778
  • 2
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 3
    Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 32736
  • 4
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 6927
  • 5
    Radzieszewski P, Dobronski P, Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A; a pilot study. Neurourol Urodynam 2001; 20: 4102
  • 6
    Zarmann DH, Ishiogooka M, Schubert J, Schmidt RA. Trigonum and bladder base injection of severe urgency–frequency syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodynam 2001; 20: 4123
  • 7
    Rapp DE, Lucioni A, Katz EE et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004; 63: 10715
  • 8
    Griffiths D. Detrusor contractility. Scand J Urol Nephrol Suppl 2004; 215: 93100
  • 9
    Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 1996; 77: 80511
  • 10
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstetrics Gynaecol 1997; 104: 13749
  • 11
    Schäfer W, Abrams P, Liao L et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodynam 2002; 21: 26174
  • 12
    Schäfer W. Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: from complex to simple. World J Urol 1995; 13: 4758
  • 13
    Griffiths DJ, Constantinou CE, Van Mastrigt R. Urinary bladder function and its control in healthy females. Am J Physiol 1986; 251: R22530
  • 14
    Richter R, Schaaf V. Botulinum-A-toxin for therapy of detrusor hyperreflexia in neurogenic bladders. Aktuelle Urologie 2002; 33: 1412
  • 15
    Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B. A pilot study. Int Urogynecol J 2003; 14: 4246
  • 16
    Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 2137
  • 17
    Grosse J, Kramer G, Schurch B, Stoher M. Repeat detrusor injections of botulinum A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance. Neurourol Urodynam 2002; 21: 385401